<DOC>
	<DOCNO>NCT00550797</DOCNO>
	<brief_summary>The researcher propose study airway asthmatic give TPI ASM8 14 day , examine protective effect allergen-induced bronchoconstriction , hyperresponsiveness airway inflammation .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy TPI ASM8 Subjects With Asthma</brief_title>
	<detailed_description>Early late asthmatic response attenuate ASM8 placebo solution.Methacholine challenge affect study medication . Other parameter unchanged .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Men woman 18 65 year age Intermittent mild moderate allergic asthma define ATS/ERS criterion History episodic wheeze shortness breath Significant acute chronic medical , neurologic , cardiovascular psychiatric illness , asthma exacerbation respiratory infection precede 6 week Use oral/injectable corticosteroid within last 60 day currently antiasthmatic drug , immunosuppressive , nonsteroidal antiinflammatory drug anticoagulant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Steroid-naive , non-smokers</keyword>
	<keyword>Mild moderate allergic asthmatic adult</keyword>
</DOC>